Case Report: Lymphoma Arising in an Ileal Pouch Anal Anastomosis After Immunomodulatory Therapy for Inflammatory Bowel Disease

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 8, 2006, Pages 1030-1034

  Schwartz, Lauren K ^a   Kim, Michelle Kang ^a   Coleman, Morton ^b   Lichtiger, Simon ^a   Chadburn, Amy ^b   Scherl, Ellen ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ANTIDIARRHEAL AGENT; BLEOMYCIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; PREDNISONE; PROCARBAZINE; SPASMOLYTIC AGENT; STEROID; TRICYCLIC ANTIDEPRESSANT AGENT; VINCRISTINE;

ADULT; ANASTOMOSIS; ANUS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COLON RESECTION; DIARRHEA; DRUG EFFECT; DRUG INFUSION; ENTERITIS; EPSTEIN BARR VIRUS; HUMAN; ILEITIS; ILEUM POUCH; IMMUNOMODULATION; IRRITABLE COLON; LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; POSTOPERATIVE PERIOD; SIMULATION; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADULT; ANASTOMOSIS, SURGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLITIS, ULCERATIVE; COLONIC POUCHES; CYCLOSPORINE; GLUCOCORTICOIDS; HUMANS; ILEUM; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; PREDNISONE;

EID: 33746342776     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.05.024     Document Type: Article

References (42)

1. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
2. Opelz G., and Dohler B. Lymphomas after solid organ transplantation. a collaborative transplant study report. Am J Transplant 4 (2004) 222-230
3. Opelz G., and Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342 (1993) 1514-1516
4. Beauparlant P., Papp K., and Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29 (1999) 148-158
5. Reijasse D., Le Pendeven C., Cosnes J., et al. Epstein-Barr virus viral load in Crohn's disease. effect of immunosuppressive therapy. Inflamm Bowel Dis 10 (2004) 85-90
6. Calaminici M.R., Sheaff M.T., Norton A.J., et al. Ileocaecal Epstein-Barr virus-positive lymphoproliferative disorder complicating Crohn's disease. Histopathology 35 (1999) 388-390
7. Dayharsh G.A., Loftus Jr. E.V., Sandborn W.J., et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 122 (2002) 72-77
8. Kumar S., Fend F., Quintanilla-Martinez L., et al. Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease. association with inflammatory bowel disease and immunosuppression. Am J Surg Pathol 24 (2000) 66-73
9. Li S., and Borowitz M.J. Primary Epstein-Barr virus-associated Hodgkin disease of the ileum complicating Crohn disease. Arch Pathol Lab Med 125 (2001) 424-427
10. Losco A., Gianelli U., Cassani B., et al. Epstein-Barr virus-associated lymphoma in Crohn's disease. Inflamm Bowel Dis 10 (2004) 425-429
11. Wong N.A., Herbst H., Herrmann K., et al. Epstein-Barr virus infection in colorectal neoplasms associated with inflammatory bowel disease. detection of the virus in lymphomas but not in adenocarcinomas. J Pathol 201 (2003) 312-318
12. Frizzi J.D., Rivera D.E., Harris J.A., et al. Lymphoma arising in an S-pouch after total proctocolectomy for ulcerative colitis. report of a case. Dis Colon Rectum 43 (2000) 540-543
13. Nyam D.C., Pemberton J.H., Sandborn W.J., et al. Lymphoma of the pouch after ileal pouch-anal anastomosis. report of a case. Dis Colon Rectum 40 (1997) 971-972
14. Bargen J.A. Chronic ulcerative colitis associated with malignant disease, 1928. Dis Colon Rectum 37 (1994) 727-730
15. Bebb J.R., and Logan R.P. Review article. does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma?. Aliment Pharmacol Ther 15 (2001) 1843-1849
16. Ekbom A., Helmick C., Zack M., et al. Extracolonic malignancies in inflammatory bowel disease. Cancer 67 (1991) 2015-2019
17. Karlen P., Lofberg R., Brostrom O., et al. Increased risk of cancer in ulcerative colitis. a population-based cohort study. Am J Gastroenterol 94 (1999) 1047-1052
18. Lewis J.D., Bilker W.B., Brensinger C., et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 121 (2001) 1080-1087
19. Loftus Jr. E.V., Tremaine W.J., Habermann T.M., et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 95 (2000) 2308-2312
20. Palli D., Trallori G., Bagnoli S., et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology 119 (2000) 647-653
21. Persson P.G., Karlen P., Bernell O., et al. Crohn's disease and cancer. a population-based cohort study. Gastroenterology 107 (1994) 1675-1679
22. Bernstein C.N., Blanchard J.F., Kliewer E., et al. Cancer risk in patients with inflammatory bowel disease. a population-based study. Cancer 91 (2001) 854-862
23. Aithal G.P., and Mansfield J.C. Review article. the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther 15 (2001) 1101-1108
24. Greenstein A.J., Gennuso R., Sachar D.B., et al. Extraintestinal cancers in inflammatory bowel disease. Cancer 56 (1985) 2914-2921
25. Dubinsky M.C. Azathioprine, 6-mercaptopurine in inflammatory bowel disease. pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2 (2004) 731-743
26. Sandborn W.J. Rational dosing of azathioprine and 6-mercaptopurine. Gut 48 (2001) 591-592
27. Sandborn W.J., Tremaine W.J., Wolf D.C., et al., North American Azathioprine Study Group. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology 117 (1999) 527-535
28. Bouhnik Y., Lemann M., Mary J.Y., et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347 (1996) 215-219
29. Connell W.R., Kamm M.A., Dickson M., et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343 (1994) 1249-1252
30. Fraser A.G., Orchard T.R., Robinson E.M., et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 16 (2002) 1225-1232
31. Korelitz B.I., Mirsky F.J., Fleisher M.R., et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 94 (1999) 3248-3253
32. Lewis J.D., Schwartz J.S., and Lichtenstein G.R. Azathioprine for maintenance of remission in Crohn's disease. benefits outweigh the risk of lymphoma. Gastroenterology 118 (2000) 1018-1024
33. Present D.H., Meltzer S.J., Krumholz M.P., et al. 6-Mercaptopurine in the management of inflammatory bowel disease. short- and long-term toxicity. Ann Intern Med 111 (1989) 641-649
34. Farrell R.J., Ang Y., Kileen P., et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 47 (2000) 514-519
35. Kandiel A., Fraser A.G., Korelitz B.I., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54 (2005) 1121-1125
36. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease. the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
37. Rutgeerts P., D'Haens G., Targan S., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117 (1999) 761-769
38. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., et al. The safety profile of infliximab in patients with Crohn's disease. the Mayo Clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
39. Hotline ACoR. FDA meeting: update on the safety of new drugs for rheumatoid arthritis (RA) and TNF inhibitors Vol. 2005 (2003), American College of Rheumatology
40. Chadburn A., Cesarman E., and Knowles D.M. Molecular pathology of posttransplantation lymphoproliferative disorders. Semin Diagn Pathol 14 (1997) 15-26
41. Knowles D.M., Cesarman E., Chadburn A., et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85 (1995) 552-565
42. Stein R.B., and Lichtenstein G.R. Complications after ileal pouch anal anastomosis. Semin Gastrointest Dis 11 (2000) 2-9